marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2023-Q3
added 11-14-2023
Adamis Pharmaceuticals Corporation Balance Sheet 2011-2024 | ADMP
Annual Balance Sheet Adamis Pharmaceuticals Corporation
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-22.5 M | 3.12 K | -4.73 M | -16.7 M | -12.3 M | 3.31 M | -4.08 M | -4.98 M | 1.18 M | 294 K | 25.3 K | |
Long Term Debt |
- | 343 K | 891 K | - | - | 2.58 M | 3.07 M | - | - | - | - | - |
Long Term Debt Current |
343 K | 350 K | 493 K | 440 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 7.44 M | 1.59 M | 113 K | 3.07 M | 3.9 M | - | - | - | - | - |
Total Current Liabilities |
11.4 M | 11.2 M | 19.9 M | 10.2 M | 11.6 M | 8.79 M | 8.61 M | 2.75 M | 3.39 M | 4.68 M | 2.89 M | - |
Total Liabilities |
11.6 M | 12.4 M | 27.4 M | 11.8 M | 11.7 M | 11.9 M | 12.5 M | 2.75 M | 2.93 M | 4.68 M | 2.89 M | 3.11 M |
Deferred Revenue |
27.8 K | 100 K | 100 K | 916 K | 1.01 M | 14.8 K | 54.5 K | - | - | - | - | - |
Retained Earnings |
-305 M | -278 M | -230 M | -182 M | -153 M | -114 M | -88.5 M | -69 M | -46.1 M | -38 M | -30.8 M | -25.9 M |
Total Assets |
10.9 M | 38.3 M | 30.9 M | 47.8 M | 58.4 M | 51.4 M | 37.8 M | 12.1 M | 15.1 M | 351 K | 169 K | 1.73 M |
Cash and Cash Equivalents |
1.08 M | 23.2 M | 6.86 M | 8.81 M | 19.3 M | 17.3 M | 4.09 M | 4.08 M | 3.77 M | - | 7.52 K | 1.24 M |
Book Value |
-651 K | 25.9 M | 3.5 M | 36 M | 46.7 M | 39.5 M | 25.3 M | 9.31 M | 12.2 M | -4.33 M | -2.72 M | -1.38 M |
Total Shareholders Equity |
-808 K | 25.9 M | 3.5 M | 33 M | 46.7 M | 39.5 M | 25.3 M | 9.31 M | 9.5 M | -4.33 M | -2.72 M | -1.38 M |
All numbers in USD currency
Quarterly Balance Sheet Adamis Pharmaceuticals Corporation
| 2023-Q3 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | 63.2 K | 157 K | 250 K | 343 K | 432 K | 1.57 M | 2.03 M | 891 K | 1.42 M | 1.96 M | 386 | 1.54 K | 2.21 M | 1.54 K | 1.54 K | - | 2.71 M | 2.83 M | 2.95 M | 3.07 M | 3.19 M | 3.3 M | 3.42 M | 3.53 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
13.9 M | 18.6 M | 11.6 M | 9.13 M | 10.7 M | 14.6 M | 12.4 M | 10.6 M | 17 M | 25.5 M | 27.4 M | 27.4 M | 27.4 M | 27.4 M | 14.8 M | 11.8 M | 11.8 M | 11.8 M | 11.7 M | 11.7 M | 11.7 M | 11.7 M | 11.9 M | 11.9 M | 11.9 M | 11.9 M | 12.5 M | 12.5 M | 12.5 M | 12.5 M | 2.75 M | 2.75 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
173 K | 27.8 K | 27.8 K | 27.8 K | 100 K | 100 K | 100 K | 100 K | 104 K | 121 K | 100 K | 100 K | 100 K | 100 K | 116 K | 116 K | 116 K | 916 K | 1.01 M | 1.01 M | 1.01 M | 1.01 M | 14.8 K | 14.8 K | 10.9 K | 14.8 K | 54.5 K | 54.5 K | 54.5 K | 54.5 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-323 M | -314 M | -305 M | -301 M | -297 M | -288 M | -278 M | -269 M | -257 M | -248 M | -230 M | -230 M | -230 M | -230 M | -181 M | -182 M | -182 M | -182 M | -153 M | -153 M | -153 M | -153 M | -114 M | -114 M | -114 M | -114 M | -88.5 M | -88.5 M | -88.5 M | -88.5 M | -69 M | -69 M | -69 M | -69 M | -55.4 M | -55.4 M | -55.4 M | -55.4 M | -44.6 M | -39.1 M | -39 M | -38 M | -36.3 M | -34.4 M | -33.5 M | -30.8 M | -29.6 M | -28.6 M | -27.1 M | -25.9 M |
Total Assets |
8.96 M | 9.08 M | 10.9 M | 12.1 M | 17.7 M | 30.5 M | 38.3 M | 45.1 M | 63.7 M | 80.7 M | 30.9 M | 30.9 M | 30.9 M | 30.9 M | 47.8 M | 47.8 M | 47.8 M | 47.8 M | 58.4 M | 58.4 M | 58.4 M | 58.4 M | 51.4 M | 51.4 M | 51.4 M | 51.4 M | 37.8 M | 37.8 M | 37.8 M | 37.8 M | 12.1 M | 12.1 M | 12.1 M | 12.1 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 14.8 M | 3.52 M | - | 351 K | 921 K | 764 K | 1.8 M | 169 K | 249 K | 371 K | 688 K | 1.73 M |
Cash and Cash Equivalents |
6.66 M | 3.1 M | 1.08 M | 2.42 M | 8.88 M | 17.8 M | 23.2 M | 28.7 M | 40.3 M | 57.6 M | 6.75 M | 6.75 M | 6.86 M | 6.86 M | 8.81 M | 8.81 M | 8.81 M | 8.81 M | 19.3 M | 19.3 M | 19.3 M | 19.3 M | 17.3 M | 17.3 M | 17.3 M | 17.3 M | 4.09 M | 4.09 M | 4.09 M | 4.09 M | 4.08 M | 4.08 M | 4.08 M | 4.08 M | 3.77 M | 3.77 M | 2.13 M | 5.4 M | 4.67 M | 120 K | 3.4 M | - | 1.42 K | 10.1 K | 720 K | 7.52 K | 1.6 K | 3.03 K | 191 K | 1.24 M |
Book Value |
-4.96 M | -9.52 M | -651 K | 3 M | 7.04 M | 15.9 M | 25.9 M | 34.5 M | 46.7 M | 55.2 M | 3.5 M | 3.5 M | 3.5 M | 3.5 M | 33 M | 36 M | 36 M | 36 M | 46.7 M | 46.7 M | 46.7 M | 46.7 M | 39.5 M | 39.5 M | 39.5 M | 39.5 M | 25.3 M | 25.3 M | 25.3 M | 25.3 M | 9.31 M | 9.31 M | 12.1 M | 12.1 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 14.8 M | 3.52 M | - | 351 K | 921 K | 764 K | 1.8 M | 169 K | 249 K | 371 K | 688 K | 1.73 M |
Total Shareholders Equity |
-5.29 M | -9.68 M | -808 K | 2.85 M | 7.04 M | 15.9 M | 25.9 M | 34.5 M | 46.7 M | 55.2 M | 5.98 M | 3.5 M | 3.5 M | 3.5 M | 33 M | 36 M | 36 M | 36 M | 46.7 M | 46.7 M | 46.7 M | 46.7 M | 39.5 M | 39.5 M | 39.5 M | 39.5 M | 25.3 M | 25.3 M | 25.3 M | 25.3 M | 9.31 M | 9.31 M | 9.31 M | 9.31 M | 9.5 M | 9.5 M | 9.5 M | 9.5 M | 10.1 M | -4.93 M | -4.98 M | -4.33 M | -3.24 M | -5.07 M | -4.25 M | -2.72 M | -2.25 M | -2.02 M | -1.23 M | -1.38 M |
All numbers in USD currency